Marvel Biosciences’ MB204 Shows Promise in Autism Study
Company Announcements

Marvel Biosciences’ MB204 Shows Promise in Autism Study

Story Highlights

Marvel Biosciences Corp (TSE:MRVL) has released an update.

Marvel Biosciences Corp. announced that their drug MB204 showed significant improvement in social behavior in a mouse model of autism after just one dose. The study, conducted in France, demonstrated a clear dose-response relationship, with high doses of MB204 enhancing social interactions beyond levels seen in normal mice. The company is optimistic about MB204’s potential and is preparing to publish the findings.

For further insights into TSE:MRVL stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskMarvel Biosciences Tests New Treatment for Fragile X Syndrome
TipRanks Canadian Auto-Generated NewsdeskMarvel Biosciences Grants Stock Options to Leadership
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App